Since 2004 ABCD has been increasingly active in assessing new diabetes therapies through nationwide audit. The history of this programme can be viewed on the following link: http://www.diabetologists-abcd.org.uk/n3/previous_ABCD_audits.htm
ABCD audits of GLP1-receptor agonists
In particular the ABCD nationwide exenatide and liraglutide audits collected real live data on over 13000 patients from over 150 centres with over 500 contributors involved. There have been 12 published papers, 23 abstracts and 13 oral presentations. ABCD also has an ongoing audit of exenatide QW.
ABCD audits of SGLT2 inhibitors
In the wake of the GLP1-receptor agonist programme, we are now focusing in particular focusing on the SGLT2 class with the nationwide dapagliflozin audit launched in Sept 2014, the canagliflozin audit launched in January 2016 and an empagliflozin audit launched in March 2017.
ABCD FreeStyle Libre Audit
This nationwide audit, our first of a device, launched in November 2017. An online tool is currently being developed but while this is awaited FreeStyle Libre users are encouraged to apply to join the audit and to start collecting the data on paper forms that are being provided especially for this purpose. For more information click here.
Other current ABCD Nationwide Audits
We have an ongoing audit of insulin degludec and nationwide audit of IDegLira launched in April 2017.